Crossmark

Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis

Crossref DOI link: https://doi.org/10.1186/s41927-019-0096-1

Published Online: 2019-12-16

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nakajima, Arata

Terayama, Keiichiro

Sonobe, Masato

Aoki, Yasuchika

Takahashi, Hiroshi

Akatsu, Yorikazu

Saito, Junya

Taniguchi, Shinji

Yamada, Manabu

Kubota, Ayako

Nakagawa, Koichi
Funding

Funding for this research was provided by:

Grant-in-Aid for Scientific Research of Japan (26462321)
License Information

Text and Data Mining valid from 2019-12-01

Version of Record valid from 2019-12-16
More Information

Article History

Received: 13 June 2019

Accepted: 10 October 2019

First Online: 16 December 2019

Ethics approval and consent to participate

: Approval for the study was received from the Ethics Committee of Toho University Sakura Medical Center, and all patients gave their written consent to participate in this study (approval number: 2013–008). All activities were performed in accordance with the ethical standards set forth in the Declaration of Helsinki.

: Not applicable.

: The authors declare that they have no competing interest.

Document is current

Any future updates will be listed below